The present invention relates to a liquid food composition, in particular a beverage, based on pea and/or fava bean proteins, having an improved mineral composition, in order to fit with human nutrition requirements and characterized in that it includes tricalcium phosphate and magnesium carbonate as only divalent salts. The invention also pertains to a process for obtaining said liquid composition, and also to the uses thereof, in particular in the food-processing field and most particularly the preparation of food formulations and specialized nutrition.

Use of a solid calcium compound in the fabrication of a hemostatic agent for reducing bleeding from a surgical site during and/or after a surgical treatment in a patient is provided, wherein the solid calcium compound is selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, calcium oxide, calcium hydroxide, hydroxyapatite, and a combination thereof.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

Provided are compounds, compositions, and methods for treatment of fungal infections. The compositions comprise the mannose disaccharide analog (2R,3S,4S,5S,6R)-2-((((3S,4R,5R)-4,5-dihydroxypiperidin-3-yl)methyl)thio)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Methods are also provided for the treatment of fungal infections comprising contacting the infected site with a therapeutically effective concentration of the present compound or compositions.

Provided are compounds, compositions, and methods for treatment of fungal infections. The compositions comprise the mannose disaccharide analog (2R,3S,4S,5S,6R)-2-((((3S,4R,5R)-4,5-dihydroxypiperidin-3-yl)methyl)thio)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Methods are also provided for the treatment of fungal infections comprising contacting the infected site with a therapeutically effective concentration of the present compound or compositions.

The present invention relates to a platelet aggregating agent containing amorphous polyphosphate as an active ingredient, wherein the polyphosphate is a Ca salt of polyphosphate. The platelet aggregating agent acts on damaged gastrointestinal mucosa in inflammatory bowel disease and exerts a platelet aggregating action, thereby allowing remission/improvement of the inflammatory bowel disease.

The present invention relates to a platelet aggregating agent containing amorphous polyphosphate as an active ingredient, wherein the polyphosphate is a Ca salt of polyphosphate. The platelet aggregating agent acts on damaged gastrointestinal mucosa in inflammatory bowel disease and exerts a platelet aggregating action, thereby allowing remission/improvement of the inflammatory bowel disease.

Disclosed herein are embodiments of therapeutic substances that contain solid sodium percarbonate for use in a bath, and packaging for the therapeutic substances. The solid sodium percarbonate can be dissolved in a liquid, such as water, to produce a hydrogen peroxide solution. Hydrogen peroxide solutions can be provide beneficial effects to a user. The titrated sodium percarbonate can be mixed with other chemicals/materials in a pre-made packaging for ease of storage and using with a bath.

Disclosed herein are embodiments of therapeutic substances that contain solid sodium percarbonate for use in a bath, and packaging for the therapeutic substances. The solid sodium percarbonate can be dissolved in a liquid, such as water, to produce a hydrogen peroxide solution. Hydrogen peroxide solutions can be provide beneficial effects to a user. The titrated sodium percarbonate can be mixed with other chemicals/materials in a pre-made packaging for ease of storage and using with a bath.